Myeloid Maturity: ATRA to Enhance Anti–PD-1?
Daniel J. Olson, Jason J. Luke
Abstract
Myeloid-derived suppressor cells (MDSC) are associated with resistance to anti-PD-1 therapies. All-trans retinoic acid (ATRA) may induce maturation of MDSCs and alter their immunosuppressive effects. Adding ATRA to pembrolizumab may target this resistance mechanism to enhance the overall impact of anti-PD-1-based immunotherapy. See related article by Tobin et al., p. 1209.
Topics & Concepts
Retinoic acidImmunotherapyTretinoinCancer researchMyeloid-derived Suppressor CellMyeloidPembrolizumabMedicineImmunologyChemistrySuppressorPharmacologyCancerImmune systemInternal medicineBiochemistryGeneImmune cells in cancerRetinoids in leukemia and cellular processesNF-κB Signaling Pathways